2998results about "Animal cells" patented technology

The invention relates to a nano antibody targeting cadherin 17 and application thereof, and relates to the technical field of immunology and molecular biology, the amino acid sequence of a complementary determining region of the nano antibody targeting cadherin 17 comprises CDR1 shown as any one of SEQ ID NO: 21-32, CDR2 shown as any one of SEQ ID NO: 34-45, and CDR3 shown as any one of SEQ ID NO: 47-58. According to the invention, an alpaca immune phage display library is constructed, a series of nano antibody molecules targeting cadherin 17 (CDH17) are screened from the alpaca immune phage display library, and functions and applications of the nano antibody are verified at various levels of CDH17 antigen protein, CDH17 target cells, CDH17 CAR-T cells and the like.

The invention relates to a high-activity recombinant XVII type collagen as well as a rapid preparation method and application thereof, and belongs to the technical field of bioengineering. The amino acid sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 1, and the nucleotide sequence of the high-activity recombinant XVII type collagen is as shown in SEQ ID NO. 2. The invention also provides a preparation method and application of the recombinant XVII type collagen. The high-activity recombinant XVII type collagen has good biological activity, has good effects of promoting cell adhesion, cell proliferation and cell migration, and can be compounded with other proteins to form raw materials of tissue engineering products, cosmetics, health care products or medicines. The high-activity recombinant XVII type collagen gene is integrated to different positions of a yeast genome through three different vectors, and the copy number of a target gene is increased, so that the expression quantity of the recombinant XVII type collagen is remarkably increased, and the yield of the high-activity recombinant XVII type collagen is effectively increased.

The invention relates to a humanized nano antibody targeting cadherin 17 and application of the humanized nano antibody, and relates to the technical field of immunology and molecular biology. The complementarity determining region of the humanized nano antibody comprises a CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, a CDR2 of which the amino acid sequence is shown as SEQ ID NO: 4 and a CDR3 of which the amino acid sequence is shown as SEQ ID NO: 6; a framework region of the humanized nano antibody comprises an FR1 of which the amino acid sequence is shown as any one of SEQ ID NO: 1 and SEQ ID NO: 8, an FR2 of which the amino acid sequence is shown as any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 11, an FR3 of which the amino acid sequence is shown as any one of SEQ ID NO: 5 and SEQ ID NO: 10, and an FR4 of which the amino acid sequence is shown as SEQ ID NO: 7. According to the humanized nano-antibody, the immunogenicity of the nano-antibody is reduced, the targeted binding activity and killing activity are improved, and the humanized nano-antibody can be used for developing immunodetection reagents, CAR-T / NK cell drugs and antibody drugs.

The present disclosure provides systems and methods for processing cells. The systems of the present disclosure may include a compartment, a three-dimensional (3D) matrix, a fluid flow path, an analysis unit, a preservation unit, or any combination thereof. The methods of the present disclosure may process cells via, for example, expansion, culturing, gene delivery, activation, or any combination thereof. The systems and methods described herein may be useful for producing cell products including, for example, cell therapy products.

The present invention relates to T lymphocytes targeting CLD18A2 and a preparation method and application thereof. The inventors have successfully found a target gene CLD18A2 suitable for developing CAR T cells from a number of tumor-related genes for the first time, and successfully prepared CAR T cells targeting CLD18A2, thereby providing a new treatment method for pancreatic cancer, gastric cancer and other tumors.

The invention provides recombinant VIII type humanized collagen and application thereof, and the recombinant VIII type humanized collagen is of a triple helix structure, has good cell adhesion activity, does not generate immunological rejection and anaphylactic reaction when being applied to a human body, is a brand new human body synthetic biological material, and has good application prospects.

Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.

The use of dual-target CAR-T cells in treating systemic lupus erythematosus and other B-cell autoimmune diseases is provided. The first target of the chimeric antigen receptor is CD19, the second target is BCMA, and specifically, the chimeric antigen receptor is a chimeric antigen receptor with a Loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ζ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.

The invention relates to a development method of an insect culture medium, which comprises the following steps: S1, constructing a double-promoter tandem vector by taking pFastBac plasmid as a skeleton; s2, establishing a baculovirus expression system; S21, transforming the double-promoter tandem vector into DH10Bac escherichia coli, so as to obtain recombinant Bacmid; s22, transfecting an Sf9 cell by using the recombinant Bacmid, so as to obtain a P0-generation baculovirus; s23, transfecting an Sf9 cell by using the P0-generation baculovirus to obtain a P1-generation baculovirus; s3, screening insect culture media: S31, providing culture media to be detected, and respectively inoculating Sf9 cells into the culture media to be detected; s32, respectively inoculating the P0-generation baculovirus or the P1-generation baculovirus into each to-be-detected culture medium for culturing; and S33, after culture is finished, detecting virus antibodies in the culture media to be detected, and screening the culture media. A comprehensive and quantitative evaluation system is established for development of the insect culture medium.

A method for automated, artificial-intelligence-based IVF microtool control includes receiving a command at a controller associated with an artificial intelligence / machine learning system (AI / ML system) and an imaging system used at least in part to operate robotic components of in vitro fertilization (IVF) module. The method includes retrieving at least one IVF microtool assembly (MA) from a tool inventory location using a first robotic mechanism of the robotics system, based at least in part on the command. The method includes retrieving at least one IVF receptacle using a second robotic mechanism of the robotics system based at least in part on the command. The method includes placing the IVF receptacle on a stage within the IVF module based on the command. The method includes positioning the at least one MA in proximity to the IVF receptacle, using the first robotic mechanism, based at least in part on the command.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant human III-type collagen for promoting angiogenesis as well as a preparation method and application of the recombinant human III-type collagen. The recombinant human III-type collagen for promoting angiogenesis has an amino acid sequence as shown in SEQ ID NO. 1. Nine different sites of the full-length natural III-type collagen are replaced by GFOGER sequences which are from the I-type collagen and are specifically combined with integrin sites, the angiogenesis promoting function of the collagen is enhanced under the condition that the total length of natural full-length amino acid is not changed, and meanwhile, four natural integrin sites with low adhesion rate are also replaced; the recombinant III-type collagen has high adhesive force, so that angiogenesis is further promoted. By means of the transformation mode, the angiogenesis rate is increased by 37% or above, the molecular weight of the translated protein is moderate, and the translated protein is easy to prepare.

The invention provides sgRNA for targeting and guiding nuclease to efficiently cut an HLA-DRA gene, a method for modifying a CAR-T cell by using the sgRNA, and a related gene editing system, reagent and kit. According to the CAR-T cell, the immunogenicity is greatly reduced, the risk of graft versus host disease and immunological rejection can be effectively reduced, and meanwhile the killing capacity of tumor cells of the CAR-T cell is not affected.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a base editing system for optimizing engineered T cells and application of the base editing system. The present invention provides a base editing system for modifying engineered T cells, comprising: i) a base editing polypeptide, and / or an expression construct encoding a base editing polypeptide, the base editing polypeptide comprising a DNA binding protein and at least one deaminase domain; ii) a guide RNA, and / or an expression construct encoding a guide RNA, the guide RNA targeting any one of TRAC, TGFBR2, PD-1, CISH, and / or FAS genomic regions, or any combination thereof. The base editing system disclosed by the invention has high efficiency of a gene editing tool and low Indel frequency, can realize accurate editing of T cell function enhancement related genes, and has important value for expanding application scenes of a base editing technology in the fields of preparation of safe and efficient engineered T cells and the like.

The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to a single-chain antibody targeting NRP1, a CAR-T cell and application of the single-chain antibody and the CAR-T cell in fibrosis treatment. Four types of high-affinity single-chain antibodies targeting mouse NRP1 antigens are obtained by immunizing mice, the single-chain antibodies are applied to second-generation CAR, T cells of mouse spleen sources are infected after virus packaging, and CAR-T cells are constructed. The CAR-T cells of the targeted NRP1 can be used for effectively killing NRP1 positive cells. In-vivo experiments show that the CAR-T cells can inhibit the growth of NRP1 positive tumor cells. The CAR-T cell can improve the mouse liver fibrosis condition, collagen in the mouse liver is reduced through treatment, and the molecular level of fibrosis markers SMA and NRP1 is reduced, it is indicated that the CAR-T cell recognizes and eliminates activated HSCs through targeting NRP1, and the fibrosis degree is reduced.

The invention relates to the technical field of antibodies, in particular to a Trop2 combined nano antibody, a chimeric antigen receptor and application of the Trop2 combined nano antibody and the chimeric antigen receptor. The Trop2-binding nano antibody provided by the invention can efficiently and specifically recognize and bind Trop2 protein, and can be used for diagnosing and treating diseases taking Trop2 molecules as markers. The invention further provides CAR and CAR-T cells which are combined with the Trop2 protein, and the CAR-T cells have a good Trop2-targeting immune clearance effect, can be used for specifically recognizing and killing cells expressing Trop2, can be used for improving and treating diseases with Trop2 molecules as markers and have a good application prospect in tumor diagnosis and treatment.

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

The present disclosure describes methods for producing a comestible food base from expended cell culture media previously utilized during cultivation of a cell-based animal food product. Generally, the disclosed method comprises growing animal cells within a bioreactor system by circulating a cell culture media through the bioreactor system, extracting circulated cell culture media from the bioreactor system, and producing the comestible food base by integrating one or more supplemental ingredients with the extracted cell culture media.

The invention belongs to the field of gene engineering. Specifically, the invention relates to a system, a tool and a method for modifying or editing target nucleotide bases, and more specifically, the invention relates to an optimized QBE base editing system and application thereof. The base editing system disclosed by the invention has the advantages of high efficiency of a gene editing tool, high product purity, low Indel frequency, low off-target frequency and abundant gene editing windows, and has important value for expanding application scenes of a base editing technology in the fields of life science basic research, agriculture, biological medicine and the like.

The invention discloses a production process for culturing nuclear polyhedrosis virus by using an S2 or SF9 cell line. The preparation method comprises the following steps: connecting a cell-penetrating peptide C105Y with DSPE-PEG2000-Mal on the surface of a lipid nanoparticle, then preparing a lipid nanoparticle LNP-C105Y by using the DSPE-PEG2000-Mal, and entrapping nuclear polyhedrosis virus DNA to obtain DNAHcNPV LNP-C105Y; the DNAHcNPV coated LNP-C105Y is inoculated into an SF9 grassland spodoptera frugiperda cell line or an S2 fruit fly cell line to be cultured, and the nuclear polyhedrosis virus is produced. On the basis of the fall webworm nuclear polyhedrosis virus, DNAHcNPV-LNP-C105Y lipid nanoparticles are synthesized and prepared by adopting a film dispersion-extrusion method to wrap the fall webworm nuclear polyhedrosis virus, and the fall webworm nuclear polyhedrosis virus is produced by inoculating the fall webworm nuclear polyhedrosis virus to SF9 and S2 cell lines. The hyphantria cunea nuclear polyhedrosis virus production process is improved, and the defect that the hyphantria cunea nuclear polyhedrosis virus production process in the prior art cannot be separated from hyphantria cunea living body feeding is overcome.

The invention relates to the technical field of medicine screening, in particular to an active substance screening platform and application thereof. The active substance screening platform comprises a cell combination; the cell combination comprises immunoregulation screening cells and antioxidant screening cells; the immunoregulation screening cell is a mouse mononuclear macrophage RAW 264.7 carrying an NF-kappa B element conserved sequence and a reporter gene; the antioxidant screening cell is a porcine small intestine epithelial cell IPEC-J2 cell carrying an ARE element conserved sequence and a reporter gene. The invention provides a screening platform based on a specific cell combination, which can quickly obtain an active substance with immune regulation, antioxidation or two functions from a large number of candidate active substances, has the advantages of low cost and high efficiency, and has important application value.

Provided is an anti-BDCA2 antibody. The anti-BDCA2 antibody can bind to a BDCA2 antigen with high specificity, has high affinity, and can effectively inhibit CpG-A from stimulating PBMCs to secrete IFNa and IgM, and thus is expected to serve as a drug for treating autoimmune diseases.

Provided is a method for biosynthesis of a human structural material type XVII collagen. The collagen comprises the amino acid sequence shown in SEQ ID NO: 2 or a variant amino acid sequence after mutation of the amino acid sequence. The variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO: 2. The collagen can promote cell adhesion and has a triple helix structure.

The present application relates to systems and methods to generate B cells genetically modified to express selected antibodies. The systems and methods can be used to: eliminate the need for classical vaccination; providing protection against infections available for current vaccination; providing protection against infections when the patient is additionally subjected to immunosuppression; and / or provides benefits provided by therapeutic antibodies, such as in the treatment of autoimmune disorders.

A method for automated, artificial-intelligence-based egg identification using optical coherence tomography (OCT) includes positioning an OCT imaging system head in proximity to a biological sample containing an oocyte, wherein the OCT is operatively coupled to an artificial intelligence / machine learning system (AI / ML system) and an imaging system, wherein the imaging system includes a camera system, and a lighting system. The method includes creating at least one three-dimensional image of the oocyte using the OCT, AI / ML system, and imaging system. The method includes using the AI / ML system to analyze the three-dimensional image, wherein an analysis includes detection of a polar body's presence or absence based at least in part on planar views of the oocyte.

The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure relates to a protein-based article comprising a film having a thickness of about 0.1 μm to about 10 mm and comprising a crosslinked network of partially ordered polypeptides, wherein each partially ordered polypeptide independently comprises a plurality of disordered domains and a plurality of ordered domains, wherein each disordered domain independently comprises a PG or GP motif and each ordered domain independently comprises a polyalanine motif or a polyproline motif.

The present disclosure provides drug-responsive domains derived from human carbonic anhydrase 2 that can modulate the protein stability of human interleukin-15 (IL15) payloads, as well as compositions and methods of use thereof.

The invention relates to the technical field of synthetic biology, in particular to polypeptide with a triple helix structure, recombinant XII type humanized collagen and application of the recombinant XII type humanized collagen. The recombinant XII type humanized collagen is successfully expressed and prepared, has a triple-helix structure and good biological activity including promotion of cell proliferation activity, cell adhesion activity and inhibition of MMP-1, is used as a biological material derived from a human body, does not generate immunological rejection and anaphylactic reaction when applied to the human body, and has a good application prospect. The composition can be used for medical or non-medical application of a plurality of tissues and organs of a human body, filling, compatibilizing or repairing, and promotion of skin compactness or wrinkle resistance and other scenes.

The invention relates to the technical field of tumor immunotherapy, in particular to a dual-targeting chimeric antigen receptor, a recombinant expression vector, an anti-tumor natural killer cell and application, and provides a PD1-DAP10-41BB-P2A-NKG2D-Ig4-CD28-41BB-CD3 zeta fusion receptor.The dual-targeting chimeric antigen receptor can target PD-L1 on the surface of a tumor cell, can also recognize NKG2DLs and can be used for preparing anti-tumor natural killer cells. The broad spectrum of the NK cells is greatly improved, and meanwhile, the immune escape of tumor cells is also reduced.